New WHO Guide to help countries expand access to essential medicines

WHO’s   new user guide for countries, ‘Selection of medicines at country level’, is based on the WHO Model List of Essential Medicines. It sets out the key actions countries should undertake to develop and update their own
national essential medicines lists based on the treatment needs of their populations and their capacity to reimburse payments for medicines.

The document also aims to support countries in progressing towards universal health coverage. Today, approximately half of the world’s population is unable to  access essential medicines. The large majority of these people live in poorer countries,
but rising prices of new medicines are also becoming a challenge for health systems in wealthy countries.

A careful selection of essential medicines is the first step in ensuring a population can obtain the quality-assured medicines it needs at an affordable price.  Countries need to do more to ensure that all people and communities can access highly
effective medicines. WHO’s new manual is a resource to do just that. 

The document, intended for policy makers in charge of national medicines and reimbursement lists, aims to increase transparency on how essential medicines are selected. Most national lists of essential medicines have several differences when compared
with WHO’s model list, which lists only medicines of proven safety and efficacy. Some national lists include medicines that bring little extra benefit to patients. Decision-makers should refer to the WHO global list to gauge the public health
value of listing certain medicines for their populations.

The essential medicines concept 

Essential medicines are: 

  • those that satisfy the priority health care needs of the population
  • selected with due regard to disease prevalence and public health relevance, evidence of efficacy and safety, and comparative cost-effectiveness
  • intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and community can afford.  

The essential medicines concept is global and forward-looking. It incorporates the need to regularly update medicines selections to reflect new therapeutic options and changing therapeutic needs; the need to ensure drug quality; and the need for continued
development of better medicines, medicines for emerging diseases and medicines to meet changing resistance patterns.

Achieving universal health coverage and equity in public health depends on access to essential, high-quality and affordable health related technologies for all. To achieve access for all by 2030, at least two billion more people will need to have access
to essential health services by 2030.

In an effort to make the Model List of Essential Medicines more readily accessible, WHO recently developed an electronic version of the list, bringing the traditional EML to computer screens, tablets and smartphones in a freely accessible, downloadable,
online database.

Link to manual: Selection of essential medicines at country level

Link to e-EML: Model List of Essential Medicines

Building Health Lab

Architect since 2002, experienced in healthcare environment design. Master in public health sciences from the Charité Medical University in Berlin. Evidence-based Design researcher at TU-Berlin, helping ensure that urban & architectural design projects build positive health effectively. Founder of the Building Health Lab. BHL Building Health Lab Is a think tank that develops urban concepts for neighborhoods as strategy to build a sustainable healthy city. Our mission is to help government, industry, and citizens develop projects with social impact that protect people and planet health. With our expertise in health and design, we support health promotion and disease management through people-centred and climate adaptive designs.